Cargando…
Eukaryotic translation initiation factor 2α kinase 2 in pancreatic cancer: An approach towards managing clinical prognosis and molecular immunological characterization
Most patients with pancreatic cancer are already in the late stages of the disease when they are diagnosed, and pancreatic cancer is a deadly disease with a poor prognosis. With the advancement of research, immunotherapy has become a new focus in the treatment of tumors. To the best of our knowledge...
Autores principales: | Du, Hao-Xuan, Wang, Hu, Ma, Xiao-Peng, Chen, Hao, Dai, Ai-Bin, Zhu, Ke-Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561166/ https://www.ncbi.nlm.nih.gov/pubmed/37818134 http://dx.doi.org/10.3892/ol.2023.14066 |
Ejemplares similares
-
GCN2-dependent phosphorylation of eukaryotic translation initiation factor-2α in Arabidopsis
por: Zhang, Yuhua, et al.
Publicado: (2008) -
Activation-dependent substrate recruitment by the eukaryotic translation initiation factor 2 kinase PERK
por: Marciniak, Stefan J., et al.
Publicado: (2006) -
Molecular evolution and functional divergence of eukaryotic translation initiation factor 2-alpha kinases
por: Krishna, K. Hari, et al.
Publicado: (2018) -
Eukaryotic translation initiation factors as promising targets in cancer therapy
por: Hao, Peiqi, et al.
Publicado: (2020) -
Stepwise assembly of the eukaryotic translation initiation factor 2 complex
por: Vanselow, Sven, et al.
Publicado: (2022)